Entero Therapeutics Appoints New Auditor, Dismisses BDO USA
Ticker: GRDX · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Entero Therapeutics swapped auditors from BDO to Marcum, effective June 1st.
AI Summary
Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) announced on June 1, 2024, a change in its certifying accountant. The company has dismissed BDO USA, P.A. as its independent registered public accounting firm and has appointed Marcum LLP as its new auditor. This change is effective immediately.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with other significant corporate events or financial scrutiny.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- BDO USA, P.A. (company) — Former Certifying Accountant
- Marcum LLP (company) — New Certifying Accountant
- June 1, 2024 (date) — Effective date of auditor change
- First Wave BioPharma, Inc. (company) — Former Company Name
FAQ
Why was BDO USA, P.A. dismissed as Entero Therapeutics' certifying accountant?
The filing states that the dismissal was not the result of any disagreement between the Company and the former accountant on any matter of accounting principles or practices or financial statement disclosure.
When did the change in certifying accountant become effective?
The change in certifying accountant became effective on June 1, 2024.
Who is the new independent registered public accounting firm for Entero Therapeutics?
Marcum LLP has been appointed as the new independent registered public accounting firm for Entero Therapeutics.
Has Entero Therapeutics previously had other former company names?
Yes, Entero Therapeutics was formerly known as First Wave BioPharma, Inc. (since 20210921), AzurRx BioPharma, Inc. (since 20141103), and BioPharma d'Azur, Inc. (since 20140331).
Did the company consult with Marcum LLP before appointing them?
Yes, the company consulted with Marcum LLP, and Marcum LLP has confirmed that they are independent and are not subject to any restrictions or limitations that would impair their ability to exercise independent judgment in the performance of their audit.
Filing Stats: 938 words · 4 min read · ~3 pages · Grade level 14.8 · Accepted 2024-06-05 17:15:42
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark
Filing Documents
- tm2416518d1_8k.htm (8-K) — 30KB
- tm2416518d1_ex16-1.htm (EX-16.1) — 3KB
- 0001104659-24-068733.txt ( ) — 204KB
- fwbi-20240601.xsd (EX-101.SCH) — 3KB
- fwbi-20240601_lab.xml (EX-101.LAB) — 33KB
- fwbi-20240601_pre.xml (EX-101.PRE) — 22KB
- tm2416518d1_8k_htm.xml (XML) — 4KB
01
Item 4.01 Change in Registrant's Certifying Accountant Entero Therapeutics, Inc. (the "Company") was notified that Mazars USA LLP ("Mazars"), the Company's independent registered public accounting firm, entered into a transaction with FORVIS, LLP ("FORVIS") whereby substantially all of the partners and employees of Mazars joined FORVIS. As a result, on the effective date of June 1, 2024, FORVIS, LLP changed its name to Forvis Mazars, LLP ("Forvis Mazars") and Mazars resigned as the Company's independent public accounting firm. The Audit Committee of the Company's Board of Directors has appointed Forvis Mazars to serve as the Company's independent registered public accounting firm effective June 1, 2024, subject to ratification by the Company's stockholders at the Company's annual meeting of stockholders. The audit reports of Mazars on the financial statements of the Company for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. During the Company's fiscal years ended December 31, 2023 and 2022, and the subsequent interim period preceding the engagement of Forvis Mazars, there were no disagreements between the Company and Mazars on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Mazars, would have cause Mazars to make reference to any subject matter of the disagreements in connection with its audit reports on the Company's financial statements. During the Company's previous fiscal years ended December 31, 2023 and 2022, and the interim period through the engagement of Forvis Mazars, Mazars did not advise the Company of any matters specified in Item 304(a)(1)(v) of Regulation S-K. The Company has requested that Mazars, review the disclosures contained in this report and has asked Mazars
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following Exhibits are being filed with this Current Report on Form 8-K. Exhibit No. Description 16.1 Letter, dated June 5, 2024, from Mazars USA, LLP to the U.S. Securities and Exchange Commission. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. June 5, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer